Transcode Therapeutics (RNAZ) Operating Expenses (2020 - 2026)

Transcode Therapeutics (RNAZ) has reported Operating Expenses for 7 consecutive years, with $6.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses rose 60.85% year-over-year to $6.8 million; the trailing twelve-month figure through Jun 2026 stood at $45.1 million (up 208.07% YoY), and the FY2025 full-year result was $28.0 million, up 78.66% from the prior year.
• Operating Expenses eased to $6.8 million in Q2 2026 per RNAZ's latest filing, from $17.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $17.8 million in Q1 2026 and bottomed at $2.2 million in Q3 2024.
• Historically, Operating Expenses has averaged $5.9 million across 5 years, with a median of $4.9 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses jumped 1224.03% in 2022, then sank 59.22% in 2024.
• Over 5 years, Operating Expenses stood at $5.5 million in 2022, then retreated by 25.44% to $4.1 million in 2023, then rose by 24.28% to $5.1 million in 2024, then surged by 214.72% to $16.0 million in 2025, then plunged by 57.64% to $6.8 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $6.8 million, $17.8 million, and $16.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.